510(k) · Cleared
ClearedHydrolyzed Collagen with 10% Chondroitin Sulfate (Psgag, Polysulfated Glycosaminoglycan) Wound Gel
Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly
Applied Nutritionals · KGN Wound Dressing With Animal-Derived Material (S)
Cleared on Oct 30, 2008 as substantially equivalent to K955506 (The Hymed Group Corp., 1996) and 4 other predicates after a 134-day review. Its family tree reaches back 5 generations to 1988.
- Decided
- Oct 30, 2008
- Review
- 134 days
- Class
- Class U
- Product code
- KGN
- Recalls
- None
- Predicates
- 5
Its longest line of descent runs back 5 generations to K881854 (1988). 17 ancestors in all. No later device cites it as a predicate yet.
- Root · 5 generations backK881854 Sorbsan Topical Wound DressingE.G. Dick & Assoc. · 1988
- 4 generations backK982597 Fibrcol Plus Collagen Wound Dressing with AlginateJohnson & Johnson Medical, Inc. · 1998
- 3 generations backK993948 Sis Wound Dressing IICook Biotech, Inc. · 2000
- 2 generations backK022127 Avagen Wound DressingIntegra Lifesciences Corp. · 2002
- 1 generation backK072113 Integra Flowable Wound Matrix, Model FWD301Integra Lifesciences Corp. · 2007 · Recalled
- This deviceK081724 Hydrolyzed Collagen with 10% Chondroitin Sulfate (Psgag…Applied Nutritionals · 2008
View FIG. 1 as a table
Line of descent and top descendants
| Generation | Number | Device | Applicant | Decided | Recalls |
|---|---|---|---|---|---|
| −5 | K881854 | Sorbsan Topical Wound Dressing | E.G. Dick & Assoc. | 1988 | — |
| −4 | K982597 | Fibrcol Plus Collagen Wound Dressing with Alginate | Johnson & Johnson Medical, Inc. | 1998 | — |
| −3 | K993948 | Sis Wound Dressing II | Cook Biotech, Inc. | 2000 | — |
| −2 | K022127 | Avagen Wound Dressing | Integra Lifesciences Corp. | 2002 | — |
| −1 | K072113 | Integra Flowable Wound Matrix, Model FWD301 | Integra Lifesciences Corp. | 2007 | 1 |
| 0 (this device) | K081724 | Hydrolyzed Collagen with 10% Chondroitin Sulfate (Psgag, Polysulfated… | Applied Nutritionals | 2008 | — |
Other ancestors by year cleared
| Year cleared | Devices | With a Class I recall |
|---|---|---|
| 1989 | 1 | 0 |
| 1990 | 1 | 0 |
| 1991 | 3 | 0 |
| 1993 | 1 | 0 |
| 1996 | 2 | 0 |
| 1998 | 1 | 0 |
| 1999 | 1 | 0 |
| 2002 | 2 | 0 |
Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.
Planning a device in KGN? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.
Top candidate predicates for a new KGN device
- #1 K231325 Corplex P / Theracor P / Allacor Pscore 17.9 · 8 generations · no Class I recall
- #2 Held for the reportin the report
- #3 Held for the reportin the report
What was it cleared against? (5)
Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.
| Type | Number | Device | Decided |
|---|---|---|---|
| * | K955506 | HycureSummary page 1…* Identification of predicate devices to which substantial equivalence is being claimed: o HyCure® Hydrolyzed Collagen K955506 o HeliDerm TM Collagen Wound Dressing K990086 o Integra ® Bilayer Matrix Wound Dr… | 1996 |
| * | K990086 | Heliderm Collagen Wound Dressings 0.5 Gram and 1.0 GramSummary page 1…claimed: o HyCure® Hydrolyzed Collagen K955506 o HeliDerm TM Collagen Wound Dressing K990086 o Integra ® Bilayer Matrix Wound Dressing K021792 o Chondroprotec® (10% Polysulfated Glycosam… | 1999 |
| * | K021792 | Bilayer Matrix Wound DressingSummary page 1…K955506 o HeliDerm TM Collagen Wound Dressing K990086 o Integra ® Bilayer Matrix Wound Dressing K021792 o Chondroprotec® (10% Polysulfated GlycosaminoGlycan) K961930 o Integra® Flowable Wound Matrix… | 2002 |
| * | K961930 | ChondroprotecSummary page 1…K990086 o Integra ® Bilayer Matrix Wound Dressing K021792 o Chondroprotec® (10% Polysulfated GlycosaminoGlycan) K961930 o Integra® Flowable Wound Matrix K072113 Description of the Device: Hydrolyzed Collagen with… | 1996 |
| * | K072113 | Integra Flowable Wound Matrix, Model FWD301Summary page 1…Dressing K021792 o Chondroprotec® (10% Polysulfated GlycosaminoGlycan) K961930 o Integra® Flowable Wound Matrix K072113 Description of the Device: Hydrolyzed Collagen with 10% Chondroitin Sulfate (PSGAG, Polysulfated glycosaminoglycan) Wound… | 2007 |
What descends from it?
No later submission names this one as a predicate yet.
Has anything in its family been recalled? (0 Class I)
No FDA recall names this device.
No ancestor or descendant has a Class I recall.
What does this lineage say?
- The line of descent spans 20 years and passes through 5 companies; a new generation was cleared every 2.7 years on median.
- 2 of the 17 ancestors have a recall of any class.
- 3 other devices also cite its predicate K955506.
How does its category compare?
All KGN devicesKGN Wound Dressing With Animal-Derived Material (S): FDA decisions, review times, recalls and adverse event reports over 20 years. 2008, this device’s year, is highlighted.
FDA decisions per year · KGN
15so far in 2026, the most since 2007
2026 to Oct 25, outlined.
Median 510(k) review, days · KGN
162in 2025
Receipt to decision; years with fewer than 3 clearances left blank.
Recalls per year · KGN
3in 2018
Class I (0 since 2007) Class II/III not classified
Adverse event reports per year · KGN
15in 2025
MAUDE reports naming product code KGN, not matched to any one device; reports are not rates.
View these four charts as a table
| Year | Decisions | Median 510(k) review, days | Recalls (Class I) | MAUDE reports |
|---|---|---|---|---|
| 2007 | 3 | 32 | 0 | 0 |
| 2008 | 6 | 87 | 0 | 1 |
| 2009 | 8 | 121 | 0 | 2 |
| 2010 | 4 | 175 | 0 | 3 |
| 2011 | 7 | 228 | 0 | 6 |
| 2012 | 8 | 123 | 0 | 4 |
| 2013 | 6 | 147 | 0 | 6 |
| 2014 | 5 | 188 | 0 | 12 |
| 2015 | 7 | 87 | 0 | 9 |
| 2016 | 4 | 164 | 0 | 6 |
| 2017 | 7 | 136 | 1 | 8 |
| 2018 | 6 | 148 | 3 | 15 |
| 2019 | 3 | 128 | 0 | 11 |
| 2020 | 5 | 279 | 0 | 17 |
| 2021 | 6 | 236 | 0 | 14 |
| 2022 | 12 | 246 | 0 | 13 |
| 2023 | 9 | 194 | 0 | 21 |
| 2024 | 13 | 83 | 0 | 15 |
| 2025 | 10 | 162 | 0 | 15 |
| 2026 | 15 | 174 | 0 | — |
What is it indicated for?
Hydrolyzed Collagen with 10% Chondroitin Sulfate Wound gel is indicated for topical use in the management of chronic and acute wounds and dermal ulcers including the local management of:
* Pressure Ulcers (Stage I-IV)
* Venous Stasis Ulcers
* Diabetic Ulcers
* First and Second Degree Burns
* Surgical wounds
* Traumatic wounds
* Superficial wounds
* Ulcers resulting from arterial insufficiency
* Grafted wounds and donor sites
For over the counter use, Hydrolyzed Collagen with 10% Chondroitin Sulfate Wound Gel may be used for:
- minor abrasions
- lacerations
- minor cuts
- minor scalds and burns
Indications for use as stated in the FDA summary.
https://510kreport.com/device/K081724 · printed Nov 6, 2026
Cite this page
510(k) Report. “K081724: Hydrolyzed Collagen with 10% Chondroitin Sulfate (Psgag, Polysulfated Glycosaminoglycan) Wound Gel.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 6, 2026. https://510kreport.com/device/K081724
Report an extraction error
Are you the manufacturer?
Record history
- FDA decision record loaded May 2, 2026
- Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
- Lineage and recalls computed Nov 3, 2026
- Page last updated Nov 3, 2026